Editorial & Opinion
Neisseria gonorrhoeae ciprofloxacin susceptibility testing and gyrA targets - Authors' reply.
| العنوان: | Neisseria gonorrhoeae ciprofloxacin susceptibility testing and gyrA targets - Authors' reply. |
|---|---|
| المؤلفون: | Rubin DHF; Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA., Mortimer TD; Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA., Grad YH; Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA. Electronic address: ygrad@hsph.harvard.edu. |
| المصدر: | The Lancet. Microbe [Lancet Microbe] 2023 Aug; Vol. 4 (8), pp. e575. Date of Electronic Publication: 2023 May 23. |
| نوع المنشور: | Letter; Comment |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101769019 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-5247 (Electronic) Linking ISSN: 26665247 NLM ISO Abbreviation: Lancet Microbe Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Oxford] : Elsevier Ltd., [2020]- |
| مواضيع طبية MeSH: | Ciprofloxacin*/pharmacology , Gonorrhea*/drug therapy, Humans ; Neisseria gonorrhoeae/genetics ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use |
| مستخلص: | Competing Interests: YHG receives or has received support from Wellcome Trust, Pfizer, and Merck; receives or has received consulting fees from GlaxoSmithKline, Quidel, and the National Basketball Association; receives or has received payment for expert testimony from Merck; and serves on the advisory board for Day Zero Diagnostics. DHFR and TDM declare no competing interests. |
| التعليقات: | Comment on: Lancet Microbe. 2023 Apr;4(4):e247-e254. (PMID: 36868257) Comment on: Lancet Microbe. 2023 Aug;4(8):e574. (PMID: 37236216) |
| References: | Antimicrob Agents Chemother. 2015 Mar;59(3):1478-86. (PMID: 25534723) PLoS Biol. 2019 Nov 12;17(11):e3000547. (PMID: 31714937) Elife. 2020 Jun 30;9:. (PMID: 32602459) Lancet Microbe. 2023 Apr;4(4):e247-e254. (PMID: 36868257) |
| معلومات مُعتمدة: | United Kingdom WT_ Wellcome Trust; R01 AI132606 United States AI NIAID NIH HHS |
| المشرفين على المادة: | 5E8K9I0O4U (Ciprofloxacin) 0 (Anti-Bacterial Agents) |
| تواريخ الأحداث: | Date Created: 20230526 Date Completed: 20230807 Latest Revision: 20240406 |
| رمز التحديث: | 20240406 |
| مُعرف محوري في PubMed: | PMC10994243 |
| DOI: | 10.1016/S2666-5247(23)00150-7 |
| PMID: | 37236213 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 2666-5247 |
|---|---|
| DOI: | 10.1016/S2666-5247(23)00150-7 |